B. Metzler Seel. Sohn & Co. Ag Ultragenyx Pharmaceutical Inc. Transaction History
B. Metzler Seel. Sohn & Co. Ag
- $9.49 Billion
- Q2 2024
A detailed history of B. Metzler Seel. Sohn & Co. Ag transactions in Ultragenyx Pharmaceutical Inc. stock. As of the latest transaction made, B. Metzler Seel. Sohn & Co. Ag holds 23,817 shares of RARE stock, worth $1.32 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
23,817
Previous 23,817
-0.0%
Holding current value
$1.32 Million
Previous $1.11 Million
12.05%
% of portfolio
0.01%
Previous 0.01%
Shares
8 transactions
Others Institutions Holding RARE
# of Institutions
287Shares Held
88.1MCall Options Held
505KPut Options Held
198K-
Vanguard Group Inc Valley Forge, PA9.78MShares$543 Million0.01% of portfolio
-
Black Rock Inc. New York, NY5.6MShares$311 Million0.01% of portfolio
-
Sands Capital Management, LLC Arlington, VA5.35MShares$297 Million0.68% of portfolio
-
Wellington Management Group LLP Boston, MA4.56MShares$253 Million0.03% of portfolio
-
Rtw Investments, LP New York, NY3.26MShares$181 Million2.24% of portfolio
About Ultragenyx Pharmaceutical Inc.
- Ticker RARE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 70,036,896
- Market Cap $3.89B
- Description
- Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...